Lakefront Biotherapeutics stock
LKFTNASDAQLakefront Biotherapeutics N.V., HealthcareISIN US36315X1019
74Score 74 out of 100, Strong
Price and trend
79 / 100
Price history
+5.0% in one yearThe chart shows daily closes over 15 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 75).
The price is 2.0% below its 52-week high. Largest decline in 15 years: 92% (February 2020 to February 2025).
Chart figures for advanced users
- SMA 50$30.26
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$29.89
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$26.08
- The lowest closing price of the last twelve months.
- Resistance$34.64
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Lakefront Biotherapeutics N.V. belongs to the Biotechnology industry (Belgium) and, with a market value of $2.26B, is number 115 of 289 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2025 it reported revenue of $1.23B (up 303.5% year on year) and earnings of $355.57M (up 333.1%).
Show more
- MEQIRI Score 74 out of 100 (Strong): rank 86 of 702 in Healthcare, median 53.
- The P/E is 3.6 (Biotechnology median 21.7, own median of recent years 11.5).
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Modestly valuedP/E 3.6, Biotechnology median 21.7, own median 11.5.Valuation 100
- Growing faster than its industryRevenue up 47.6% a year since 2021, Biotechnology median 19.4%.Growth 70
- High marginNet margin 46.8% over the last 12 months, Biotechnology median −103.7%.Profitability 90
Weaknesses
- Negative free cash flowFree cash flow −$300.64M over the last 12 months.Fundamentals 43
- DilutionShare count up 18% since 2021.Capital allocation 55
Its standout strengths are valuation and stability, while fundamentals holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 73 to 74.
One-off effect in revenue
In the quarter to 31 Dec 2025, revenue of $998.2M was about 13 times the usual level. P/E, margin, growth and score for the last twelve months depend on it.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
What lowers it
- price near its 52-week high
Valuation
Valuation signal
UndervaluedA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 304% on the prior year. Revenue has grown strongly since 2021, at around 48% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 97%, operating 45%, net 29%. Last 12 months: net 47%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 11 Nov 2026above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −2.53+0.4%
- Revenue
- $35.68M−0.3%
- Earnings per share
- −2.41+0.3%
- Revenue
- $43.69M−0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −0.8%Year end 2026 cash now expected at EUR 1.975 billion to EUR 2.05 billion; the company did not state the direction versus before.
“Inclusive of the Ouro-related expenditures and continued wind-down of cell therapy, we now expect to end the year with EUR 1.975 billion to EUR 2.05 billion of cash and cash equivalents.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Lakefront Biotherapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 74
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- NewAmsterdam PharmaNAMS $2.4B35
- PharvarisPHVS $2.38B44
- Zealand PharmaZEAL.CO $2.37B59
- Replimune GroupREPL $2.31B42
- Celldex TherapeuticsCLDX $2.24B34
- Palvella TherapeuticsPVLA $2.24B44
- ImmunomeIMNM $2.21B36
- Alamar BiosciencesALMR $2.21B47
ETFs that hold Lakefront Biotherapeutics
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI EMU Small Cap UCITS ETFSXRJ | 0.17% | 0.58% | €838.19M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.12% | 0.40% | €1.5B |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.11% | 0.30% | €813.64M |
Show 5 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.09% | 0.23% | €321.86M |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.08% | 0.40% | €580.62M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.06% | 0.30% | €3.45B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.03% | 0.35% | €1.25B |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.03% | 0.34% | €16.96M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 23 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.